The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against Hormone-Dependent Endometrial Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The past few years have seen an increase in the reported incidence of endometrial carcinoma, one of the most frequently diagnosed malignancies of the female genital tract. Estrogen production is vital for the mitogenesis of endometrial tumors. Inhibition of steroid sulfatase (STS), an enzyme responsible for the synthesis of steroids with estrogenic properties, may represent a novel therapeutic target for this type of cancer. This study investigates the effects of STX64 (also known as 667Coumate and BN83495) and STX213, two potent STS inhibitors, on hormone-dependent endometrial cancer cell growth in vivo. When tested in intact mice with endometrial cancer xenografts, STX64 had limited effect on tumor growth. In contrast, the microtubule disruptor STX140 reduced tumor growth by 55%. In a hormone-dependent endometrial xenograft model in ovariectomized mice, both STX64 and STX213 given orally, daily at 1 mg/kg significantly inhibited tumor growth by 48 and 67%, respectively. However, when given orally at 1 mg/kg once weekly, only STX213 still inhibited tumor proliferation. At a higher dose of STX64 (10 mg/kg, orally, daily), a greater tumor growth inhibition of 59% was observed. Liver and tumor STS activity was completely inhibited in all daily treatment groups. Plasma estradiol (E2) levels were also significantly decreased. A significant correlation was observed between plasma E2 concentrations and STS activity, indicating the importance of circulating E2 on tumor growth. This novel study demonstrates for the first time that STS inhibitors are potent inhibitors of endometrial cancer growth in nude mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroid sulfatase: molecular biology, regulation, and inhibition
Reed, M. J., Purohit, A., Woo, L. W. L., Newman, S. P., & Potter, B. V. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0003 · Cited by 524
Self-citationSteroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma
Utsunomiya, H., Ito, K., Suzuki, T., Kitamura, T., Kaneko, C., Nakata, T., Niikura, H., Okamura, K., Yaegashi, N., & Sasano, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0040 · Cited by 85
17β-hydroxysteroid dehydrogenases in human endometrium and its disorders
Ito, K., Utsunomiya, H., Suzuki, T., Saitou, S., Akahira, J.-I., Okamura, K., Yaegashi, N., & Sasano, H. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.038 · Cited by 54
Cited by
The Regulation of Steroid Action by Sulfation and Desulfation
Mueller, J. W., Gilligan, L. C., Idkowiak, J., Arlt, W., & Foster, P. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1036 · Cited by 419
Self-citationSteroid sulfatase inhibitors for estrogen- and androgen-dependent cancers
Purohit, A., & Foster, P. A. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0266 · Cited by 126
“Similar results were also shown in a xenograft estrogen-driven mouse model of endometrial cancer (Foster et al. 2008c).”
Self-citationThe important roles of steroid sulfatase and sulfotransferases in gynecological diseases
Rižner, T. L. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00030 · Cited by 98
Potter, B. V. L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0045 · Cited by 73
Self-citationSteroid sulphatase and its inhibitors: past, present, and future
Foster, P. A. (2021) · Molecules · doi:10.3390/molecules26102852 · Cited by 49
“Briefly, early pre-clinical research identified the potential for STS inhibitors to be a successful strategy against oestrogen responsive endometrial cancer [99].”
BackgroundSelf-citation
Metadata
- Authors
- Foster, P. A., Woo, L. W. L., Potter, B. V. L., Reed, M. J., & Purohit, A.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 149
- Issue
- 8
- Pages
- 4035-4042
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2080322268
- Cited by
- 43
- References
- 3
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.